TORONTO, ON, April 17, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces it is moving towards a letter of intent after initiating negotiations with 2 AMPR applicants, one having received a Health Canada Compliance number towards a Canadian Marijuana cultivators / growers license; provides other updates.
As per its previously announced negotiations with an AMPR applicant and new recent positive developments, Easton Pharmaceuticals will be forwarding a letter of intent to one AMPR applicant for a possible investment. Easton is currently in negotiations with 2 AMPR applicants with one of the companies having received approval and a Health Canada compliance number on its AMPR application for a marijuana cultivators / growers license to meet the federal medical / recreational launch of Marijuana for the country of Canada. These negotiations are as a result of Easton’s ongoing quest to acquire businesses and assets in various pharmaceutical sectors and other growing industries to build shareholder value.
In other developments, as a result of conducted assessments, Easton and its newly formed board of directors is preparing to soon provide its shareholders with full details on decisions made regarding its various businesses and partnerships, some of which includes ones that Easton has previously provided investment capital towards. Some of its decisions may involve either abandoning negotiations on some if its previously executed and announced initiatives, while undertaking changes on other businesses and partnerships involving some of its women’s diagnostic and treatments for the Mexico market while it waits along with its partner BMV Medica for BAYER to launch its licensed product VS-Sense following the execution of a sub-distribution agreement.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica S.A. and together own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis. In addition a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts. Easton has closed on an agreement with Ontario based Alliance Group to acquire a 50% property ownership interest and a 20% to 70% ownership interest in 2 businesses, which includes aggregate and the cultivation and distribution of medical / recreational marijuana.
For More Information On Easton and Affiliated and Partner Company's Visit:
http://www.eastonpharmaceuticalsinc.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.